RxDoctor Payments DataLook up a doctor →

Vivian Allen, APRN

Adult Health · Brunswick, GANPI 1912089590

Payments from drug & device makers

$8,989in general payments, 2019–2025

Across 398 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$720
  • AstraZeneca$485
  • UCB, Inc.$420
  • Novartis$356
  • Lundbeck LLC$338
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$8,90099%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,989 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.

See all adult health providers in Georgia

Medicare billing

Part B allowed, 2024
$25,119
Medicare patients
203
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate17$144,967
RebifInterferon Beta-1a/Albumin13$144,119
Nurtec OdtRimegepant Sulfate64$94,238
QuliptaAtogepant53$82,867
UbrelvyUbrogepant49$58,746
Aimovig AutoinjectorErenumab-Aooe30$41,512
BriviactBrivaracetam23$35,323
Topiramate ErTopiramate33$35,214
FycompaPerampanel21$25,849
NourianzIstradefylline11$22,886
Emgality PenGalcanezumab-Gnlm22$18,147
GraliseGabapentin11$13,803
Lacosamide143$12,838
Ajovy AutoinjectorFremanezumab-Vfrm12$11,539
NamzaricMemantine Hcl/Donepezil Hcl13$11,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Namzaric$1,414$152,770115 claims
Acadia Pharmaceuticals IncNuplazid$236$144,96717 claims
EMD Serono, Inc.Rebif$152$144,11913 claims
PfizerNurtec Odt$720$94,23864 claims
UCB, Inc.Briviact$420$35,32323 claims
Eisai Inc.Fycompa$298$25,84921 claims
Kyowa Kirin, Inc.Nourianz$176$22,88611 claims
Upsher-smith Laboratories LLCTopiramate$62$2,246140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 577 adult health providers in Georgia.

Other adult health in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →